Table 2: Rejection severity.
|
|
Alemtuzumab |
Basiliximab |
Thymoglobulin |
p value |
|
Rejection Severity |
|
|
|
0.3813 |
|
Borderline |
19 (55.9%) |
14 (51.9%) |
21 (77.8%) |
|
|
IA |
8 (23.5%) |
7 (25.9%) |
5 (18.5%) |
|
|
IB |
5 (14.7%) |
2 (7.4%) |
0 (0.0%) |
|
|
IIA |
1 (2.9%) |
1 (3.7%) |
1 (3.7%) |
|
|
IIB |
1 (2.9%) |
2 (7.4%) |
0 (0.0%) |
|
First diagnosed rejection classified according to Banff 2017 criteria showed no significant difference among the three induction agents. Patients who received Basiliximab for induction had 7.4% increase incidence of IIB rejection when compared to 2.9% with Alemtuzumab and 0% with Thymoglobulin. P = 0.3.